Linolenic acid

Elcella capsules, a new weight loss pill developed by Dr. Madusha Peiris, offer benefits similar to Ozempic without harmful side effects. Comprising flaxseed, coconut, and MCT oils, they trigger natural appetite-reducing hormones, aiding in significant weight loss. Currently in clinical trials, Elcella promises a cheaper, natural alternative to existing weight-loss drugs.

Dermatology Times covers advancements in skin cancer, atopic dermatitis treatments, psoriasis care, photodynamic therapy, and more, with expert insights and FDA approvals.

Ameluz (BF-200 ALA) plus photodynamic therapy (PDT) significantly improved lesion clearance in patients with superficial basal cell carcinoma (sBCC) compared to placebo-PDT, according to phase 3 ALA-BCC-CT013 trial results. The trial's primary endpoint showed 65.5% success rate in Ameluz arm vs 4.8% in placebo arm. Complete histological and clinical clearance rates were 75.9% vs 19.0% and 83.4% vs 21.4%, respectively. The FDA submission is expected by end of 2025 after 1-year follow-up.

Higher alpha-linolenic acid (ALA) levels linked to longer survival and slower ALS progression. CAP-1002 shows improved cardiac function in DMD patients over 2 years. FDA grants traditional approval to Eisai’s Alzheimer’s drug lecanemab, expanding access for the aging population.